BNP Paribas Financial Markets Has $63,000 Stock Holdings in Cardlytics, Inc. (NASDAQ:CDLX)

BNP Paribas Financial Markets raised its stake in shares of Cardlytics, Inc. (NASDAQ:CDLX) by 32.1% during the third quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 19,745 shares of the company’s stock after purchasing an additional 4,796 shares during the quarter. BNP Paribas Financial Markets’ holdings in Cardlytics were worth $63,000 as of its most recent filing with the Securities and Exchange Commission.

Several other large investors also recently modified their holdings of the stock. Dynamic Technology Lab Private Ltd bought a new position in shares of Cardlytics during the 3rd quarter worth approximately $153,000. Charles Schwab Investment Management Inc. raised its stake in Cardlytics by 3.0% during the third quarter. Charles Schwab Investment Management Inc. now owns 390,343 shares of the company’s stock worth $1,249,000 after acquiring an additional 11,388 shares in the last quarter. Intech Investment Management LLC bought a new position in shares of Cardlytics during the third quarter valued at $47,000. Check Capital Management Inc. CA boosted its stake in shares of Cardlytics by 10.4% in the 3rd quarter. Check Capital Management Inc. CA now owns 50,650 shares of the company’s stock valued at $162,000 after purchasing an additional 4,775 shares in the last quarter. Finally, Brooktree Capital Management grew its holdings in shares of Cardlytics by 24.7% in the 3rd quarter. Brooktree Capital Management now owns 167,642 shares of the company’s stock worth $536,000 after purchasing an additional 33,169 shares during the last quarter. 68.10% of the stock is currently owned by institutional investors.

Cardlytics Price Performance

Shares of CDLX stock opened at $3.55 on Friday. Cardlytics, Inc. has a 1 year low of $2.89 and a 1 year high of $20.52. The company has a current ratio of 1.18, a quick ratio of 1.18 and a debt-to-equity ratio of 2.40. The firm’s 50 day moving average is $3.93 and its 200-day moving average is $5.30. The firm has a market capitalization of $180.42 million, a price-to-earnings ratio of -0.58 and a beta of 1.53.

Cardlytics (NASDAQ:CDLX) last posted its quarterly earnings data on Wednesday, November 6th. The company reported ($0.15) earnings per share for the quarter, topping the consensus estimate of ($0.33) by $0.18. The firm had revenue of $67.06 million during the quarter, compared to analysts’ expectations of $57.77 million. Cardlytics had a negative net margin of 93.55% and a negative return on equity of 110.67%. Cardlytics’s revenue was down 15.1% on a year-over-year basis. During the same quarter in the previous year, the company posted ($0.26) EPS. Sell-side analysts forecast that Cardlytics, Inc. will post -1.52 EPS for the current fiscal year.

Insider Activity

In other news, CFO Alexis Desieno sold 25,118 shares of the firm’s stock in a transaction on Friday, November 15th. The stock was sold at an average price of $3.43, for a total value of $86,154.74. Following the transaction, the chief financial officer now directly owns 116,481 shares in the company, valued at $399,529.83. This trade represents a 17.74 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, CEO Amit Gupta sold 22,607 shares of the stock in a transaction dated Thursday, October 24th. The shares were sold at an average price of $3.85, for a total value of $87,036.95. Following the completion of the transaction, the chief executive officer now directly owns 178,519 shares in the company, valued at $687,298.15. The trade was a 11.24 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 68,691 shares of company stock valued at $237,767 over the last 90 days. 4.40% of the stock is owned by company insiders.

Analyst Ratings Changes

Several equities analysts recently issued reports on the stock. Evercore ISI began coverage on shares of Cardlytics in a report on Friday, October 11th. They set an “in-line” rating and a $4.00 price target for the company. Needham & Company LLC reiterated a “hold” rating on shares of Cardlytics in a research note on Thursday, November 7th. Finally, Craig Hallum upgraded Cardlytics from a “hold” rating to a “strong-buy” rating in a research report on Wednesday, November 6th. One equities research analyst has rated the stock with a sell rating, five have given a hold rating and one has given a strong buy rating to the company. Based on data from MarketBeat.com, the stock has an average rating of “Hold” and a consensus target price of $6.92.

Cardlytics Company Profile

Cardlytics, Inc operates an advertising platform in the United States and the United Kingdom. It offers Cardlytics platform, a proprietary native bank advertising channel that enables marketers to reach customers through their network of financial institution partners through digital channels, such as online, mobile applications, email, and various real-time notifications; and Bridg platform, a customer data platform which utilizes point-of-sale data and enables marketers to perform analytics and targeted loyalty marketing, as well as measure the impact of their marketing.